Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings (NASDAQ: BPTH) will hold a conference call on May 17, 2022, at 8:30 a.m. ET to discuss its Q1 financial results for the period ending March 31, 2022. The call will offer a business overview and can be accessed by phone or via a live audio webcast on the company's website. Bio-Path is advancing its proprietary DNAbilize^® technology, with lead candidate prexigebersen in a Phase 2 study for blood cancers and plans for Phase 1 studies of BP1001-A in solid tumors. The company aims to file an IND for BP1003 in 2022.

Bio-Path Holdings (NASDAQ: BPTH) presented preclinical data for BP1003, a novel cancer therapy, at the 2022 AACR Annual Meeting. The findings suggest that BP1003 enhances the efficacy of standard chemotherapies like paclitaxel and 5-FU in treating breast and ovarian cancers. CEO Peter Nielsen expressed excitement about these results, indicating plans to file an IND application and initiate clinical studies for BP1003. The drug targets the STAT3 pathway, which is associated with cancer progression and drug resistance, showcasing potential for advanced solid tumor treatment.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) appointed Aline Sherwood to its Board of Directors on March 31, 2022, following the resignation of Martina Molsbergen on February 14, 2022. Sherwood, a seasoned communications leader with extensive biotech experience, will help enhance the company's messaging in the clinical and financial sectors. Her role is expected to support Bio-Path's advancement in developing cancer therapies using its proprietary DNAbilize^® technology. The company is focused on critical cancer treatments, with several candidates currently in trials.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its financial results for the year ending December 31, 2021, reporting a net loss of $10.4 million, or $1.55 per share, a slight improvement from the $10.9 million loss in 2020. Research expenses decreased to $5.9 million, while general administrative expenses rose to $4.5 million. The company also highlighted successful data presentations at recent medical conferences and maintained cash reserves of $23.8 million, up from $13.8 million the previous year. Key milestones are anticipated as clinical trials progress.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced an upcoming poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from April 8-13, 2022. Dr. Maria Gagliardi will present pre-clinical studies of BP1003, a liposomal STAT3 antisense agent, aimed at treating breast and ovarian cancer cells in combination with chemotherapy drugs. The presentation is scheduled for April 12, 2022, from 1:30-5 PM ET, focusing on enhancing treatment efficacy.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a conference call on March 11, 2022, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2021, along with a business overview. The company utilizes its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop targeted cancer drugs. Key products include prexigebersen, in a Phase 2 study for blood cancers, and prexigebersen-A, which has FDA clearance for a Phase 1 study in solid tumors. An IND application for BP1003 is expected in 2022.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced that CEO Peter Nielsen will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. The pre-recorded presentation will be accessible via an audio webcast on Bio-Path's website for 90 days post-event. Bio-Path focuses on developing targeted cancer drugs using its proprietary DNAbilize® RNAi technology. Its lead candidate, prexigebersen (BP1001), is currently in Phase 2 trials for blood cancers, while other products are also in development for various cancers.

Bio-Path Holdings (NASDAQ: BPTH) recently showcased preliminary data at the 2021 ASH Annual Meeting, demonstrating the safety and efficacy of prexigebersen in high-risk AML patients. The Phase 2 study involved patients treated with prexigebersen combined with decitabine and venetoclax. Key outcomes indicated that 50% of patients receiving the prexigebersen + decitabine regimen achieved responses, while 67% of those on the combination therapy with venetoclax reached complete remission. These results are promising for a challenging patient population.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) reported its Q3 2021 financial results, achieving a net loss of $2.1 million, or $0.29 per share, compared to a $3.0 million loss or $0.80 per share in Q3 2020. The company saw a decrease in R&D expenses to $1.0 million from $2.0 million, while G&A expenses rose slightly to $1.1 million. Bio-Path highlighted recent corporate milestones, including FDA clearance for two clinical trials: prexigebersen-A for solid tumors and BP1002 for relapsed AML patients. As of September 30, 2021, the company had $26.6 million in cash.